Haemonetics (HAE) reported fiscal Q4 adjusted earnings Thursday of $1.24 per diluted share, up from $0.90 a year earlier.
Analysts polled by FactSet expected $1.22.
Revenue for the quarter ended March 29 was $330.6 million compared with $343.3 million a year earlier.
Analysts surveyed by FactSet expected $329.4 million.
The company said it expects fiscal 2026 adjusted earnings of $4.70 to $5 per diluted share on report revenue growth of 3% to 6%. Analysts surveyed by FactSet expect adjusted earnings of $4.92 per share on revenue of $1.33 billion.
Shares of the company down nearly 2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.